Cleerly Unveils Groundbreaking Late-Breaking Clinical Trial Results Demonstrating AI-QCT's Predictive Power for Women's Cardiovascular Risk at ACC.25
New Findings from the CONFIRM2 Registry Reveal Significant Gender Disparities in Coronary Plaque Features and Associated Risks for Major Adverse Cardiovascular Events
DENVER, March 31, 2025--(BUSINESS WIRE)--Cleerly, the leader in cardiovascular AI imaging, has announced revolutionary findings from its late-breaking clinical trial presented at the American College of Cardiology's Annual Scientific Session + Expo (ACC.25) in Chicago, Illinois. The study, titled "Artificial Intelligence-based Quantitative Computed Tomography (AI-QCT) Coronary Plaque Features Predict Risk More Pronounced in Females: The International Multicentric Registry CONFIRM2," was led by Gudrun M. Feuchtner, MD, MBA, and presented during the Clinical and Investigative Horizons I session on March 31st, 2025. This research is simultaneously published today in Circulation: Cardiovascular Imaging, a peer-reviewed journal of the American Heart Association.
The findings demonstrate that AI-QCT features of coronary artery disease (CAD), as detected by Cleerly's AI-QCT, can identify women at high risk for major adverse cardiovascular events (MACE) and improves risk stratification - a population that has historically been underdiagnosed and undertreated for CAD.
The CONFIRM2 study is notable for including approximately 50% female participants and a diverse cohort of 3,500 individuals from 11 countries, highlighting the broad applicability of these findings in addressing cardiovascular health disparities.
Key Findings on Gender Disparities in Cardiovascular Risk
Higher Risk for Women: Despite a higher total AI-QCT CAD burden in men, similar increases in AI-QCT-derived plaque features (total plaque volume, calcified plaque, non-calcified plaque, and percentage atheroma volume) confer a significantly higher risk for MACE in women. Traditional risk scores performed poorly, while AI-QCT added significant predictive value for both sexes.
Enhanced Detection and Risk Stratification: Cleerly's AI-QCT improves the detection and characterization of coronary atherosclerosis, offering more precise prognostic risk stratification for MACE that surpasses traditional risk factors.
Gender-Specific Insights: AI-QCT reveals that certain coronary plaque features present a higher risk of MACE in women compared to men, emphasizing the need for tailored preventive strategies for women.
Prognostic Value Consistency: The analysis shows that AI-QCT has strong prognostic value in both women and men, with stenosis and non-calcified plaque identified as the strongest independent predictors in women.
Implications for Women's Heart Health
These findings underscore the urgent unmet need to integrate AI-QCT into clinical practice for unbiased risk estimation in both men and women.
Enhanced Precision & Personalization: Using AI-QCT-based risk stratification instead of traditional risk scores strongly enhances precision and enables tailored preventive care.
Addressing Underdiagnosis & Undertreatment: Transitioning to an AI-QCT-based approach may eliminate bias and tackle the longstanding issue of underdiagnosis and undertreatment of CAD in women, ultimately improving outcomes.
Increased Awareness & Tailored Therapies: AI-QCT's ability to identify higher risk in women should drive greater awareness and prompt reinforced anti-atherosclerotic therapies and other preventive measures tailored specifically to women.
Potential for Sex-Specific Guidelines: These insights may lead to the development of sex-specific treatment guidelines, ensuring women receive the most appropriate and effective care for their cardiovascular health.
"This research is a significant step forward in addressing the historical disparities in cardiovascular care for women. AI-QCT provides physicians with a powerful, unbiased tool that not only enhances detection but also enables more precise risk prediction and personalized care. These findings underscore the urgency of incorporating AI-QCT into clinical practice to improve outcomes for all patients, and especially for women," said Gudrun M. Feuchtner, MD, MBA, lead researcher of the study, from Medical University Innsbruck, Austria, on behalf of the CONFIRM2 investigator group led by Principal Investigator Alexander van Rosendael, MD, PhD, from Leiden University Medical Center and Ibrahim Danad, MD, from Radboud Medical University Center, Netherlands.
About Cleerly
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250331797775/en/
Contacts
Cleerly Media Contact Christy Sievertpress@cleerlyhealth.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Android Authority
an hour ago
- Android Authority
Samsung could turn the Galaxy S26 series into Perplexity phones
Joe Maring / Android Authority TL;DR Samsung is reportedly close to signing a deal with Perplexity to preload its services on Galaxy phones. The deal would see Perplexity's app and assistant installed on Galaxy devices, while its tech could be integrated into Bixby. The companies could announce these integrations later this year before kicking things off on the Galaxy S26 series. Samsung has a close partnership with Google and Microsoft when it comes to services on its Galaxy phones. Now, it sounds like a major AI player could be available out of the box on the Galaxy S26 series. Bloomberg reports that Samsung is close to inking a deal with Perplexity to preload its services and technologies on Galaxy phones, citing sources familiar with the matter. The deal could also see Samsung become one of the AI firm's biggest investors as part of a new round of funding. The outlet claims that Perplexity's assistant and app would be preloaded on Samsung phones, while its search features would be integrated into the Samsung Internet Browser. The companies are also apparently thinking about integrating Perplexity's technology into the Bixby assistant. Do you use Perplexity? 0 votes Yes, all the time NaN % Yes, now and again NaN % No, I don't NaN % Samsung and Perplexity could announce the partnership later this year. However, the companies are reportedly aiming to include Perplexity as the 'default assistant option' on the Galaxy S26 series. The companies might not stop here, though. They've reportedly talked about developing an 'AI-infused' operating system and an 'AI agents' app that would support Perplexity and other AI assistants. Samsung wouldn't be the first Android brand to offer integration with Perplexity, as Motorola beat it to the punch last month. Samsung also has a tight relationship with Google, but it wouldn't be the first time it considered a deal with one of Google's rivals. Samsung apparently considered a switch from Google to Bing in 2023 before ultimately sticking with the search kingpin. Got a tip? Talk to us! Email our staff at Email our staff at news@ . You can stay anonymous or get credit for the info, it's your choice.
Medscape
2 hours ago
- Medscape
Same-Day Discharge Criteria Outlined for AF Ablation
SAN DIEGO — Same-day discharge after ablation of atrial fibrillation (AF) is an appropriate strategy for saving costs if performed with strict selection criteria and protocols, according to a recently issued joint statement from the American College of Cardiology and the Heart Rhythm Society. Same-day discharge has long been indicated for catheter ablations to abort routine atrial flutter, atrioventricular nodal reentrant tachycardia, and focal atrial tachycardias, according to the authors of the new joint statement. Although they maintained patients selected for elective catheter ablation of AF require heightened scrutiny, they endorsed same-day AF ablation when used selectively. The statement evaluates 'evidence supporting shorter hospitalization stay with same-day discharge for intracardiac ablations agonistic to site of care,' reported Amit J. Shankar, MD , an electrophysiologist with Canton-Potsdam Hospital in Potsdam, New York, who served as a representative for the Heart Rhythm Society in developing the statement. Whether in a hospital setting or an outpatient facility, the statement describes same-day discharge ablation as an opportunity to improve patient access, improve efficiency, and reduce healthcare costs. The adoption of same-day discharge after AF ablation was accelerated during the COVID-19 pandemic, said Samuel O. Jones, MD, a cardiologist affiliated with The Chattanooga Heart Institute in Chattanooga, Tennessee, and a fellow of the American College of Cardiology. 'Improved workflows, technological innovations, and procedure advancements have also contributed to the high rates at which these are performed,' added Jones, who helped write the statement. The statement was released on April 24 to coincide with the first day of the Heart Rhythm Society (HRS) 2025 annual scientific meeting. It was simultaneously published in Heart Rhythm and the Journal of the American College of Cardiology . The scientific statement's recommendation is intended for elective rather than urgent or emergency ablations. Support for the statement was drawn from multiple case-controlled studies, meta-analyses, and outcome databases. In one example, a 12-study meta-analysis with data from more than 18,000 elective ablations showed no significant differences in major complications from the procedure among the 40.5% of patients discharged the same day relative to those who were discharged after at least one night in the hospital. In another study, drawn from a real-world prospective registry, outcomes were compared for potential candidates for same-day ablation on the basis of prespecified criteria and those who were not eligible for the procedure. These criteria included no bleeding history, a left ventricular ejection fraction greater than 40%, no pulmonary disease, and no surgical procedures within the previous 60 days. Of the 2332 patients included in the analysis, 1982 (85%) were deemed candidates for same-day ablation. Although freedom for atrial arrhythmias was comparable ( P = .0212) for the two groups, patients discharged the same day had a lower rate of complications (0.8% vs 2.9%; P < .001). The rate of readmission was similar (0.8% vs 09%; P = .924), according to the researchers. Contraindications for Same-Day Ablation In the document, relative contraindications for same-day ablation include decompensated heart failure, significant pulmonary disease, significant risk of bleeding, and any major unstable comorbidities such as diabetes, hypertension, or renal disease. The document recommends limiting same-day procedures to patients who can have readily available social support and can return to a hospital quickly in the event of a post-procedural complication. Acknowledging that most large hospitals offering ablation for AF already have formal selection criteria and protocols in place for same-day discharge, the authors called for free-standing sites to establish their own if they have not done so. In these settings, the authors emphasized the need to rigorously follow prespecified and 'ironclad' selection criteria and protocols. From this standpoint, Shankar said same-day procedures should always be performed on the basis of shared decision-making with the patient. While the economic benefits of same-day procedures might be shared by the facility and the patient, the latter should understand the inherent differences in the settings and participate actively in any decision of where the ablation is performed. Jones said while a substantial body of evidence supports same-day AF ablation as a safe and effective procedure that can free up necessary resources in the healthcare facility, the potential advantages are relevant only to appropriately selected patients. The new statement also suggests transfer agreements with inpatient facilities should be arranged in advance and that patients should be informed such a transfer is a possibility outside of a hospital setting. However, the document makes clear same-day ablations in alternative sites of care are reasonable when the precautions are observed. In any setting that AF ablation is performed, the writing committee encouraged tracking outcomes to ensure that high-quality care is achieved and sustained. Shankar and Jones reported no potential conflicts of interest.
Business Wire
2 hours ago
- Business Wire
CARMAT Announces the First Commercial Implants of Its Aeson® Artificial Heart Outside the European Union
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces the first implants of its Aeson® artificial heart in a commercial set-up, outside the European Union (EU). Two implants of Aeson® artificial heart were performed during the week commencing May 26, 2025 in Israel. The first one was carried out at Hadassah Ein Kerem Hospital in Jerusalem by a team led by Pr Offer Amir, Pr Rabea Asleh and Dr Amit Korach, respectively director of the Heart Institute, director of heart failure unit and director of the cardiac surgery department at Hadassah Medical Center. The second one was carried out at Sheba Medical Center in Ramat Gan (Tel Aviv), by a team led by Dr Jeff Morgan, Dr Leonid Sternik, Dr Alex Fardman and Dr Eyal Nachum, respectively head of mechanical support unit, director of cardiac surgery department, heart failure cardiologist and cardiac transplant surgeon. Those are the first Aeson® implants made in a commercial set-up outside the European Union. These implants bring to 5 the total number of countries 1 where commercial implants have been performed so far. They confirm the trust placed in the device by healthcare professionals, and the growing interest in the therapy. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company's current cash runway is limited to mid-June 2025 (excluding the flexible equity financing line entered into with IRIS, which was announced on March 27, 2025). The Company is also subject to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the pace and results of ongoing or planned clinical trials, technological evolution and competitive environment, regulatory changes, industrial risks, and all risks associated with the Company's growth management. The Company's forward-looking statements mentioned in this press release may not be achieved due to these elements or other risk factors and uncertainties, whether unknown or not considered material and specific by the Company as of today. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).
